Close Menu

NEW YORK – OncoCyte said after the close of the market on Friday that it has entered into an agreement to acquire all of the outstanding capital stock of privately held Insight Genetics, including a lung cancer immunotherapy test in development by the firm.

According to OncoCyte, the acquisition also gives it access to IG's existing pharma services infrastructure, which includes a CLIA-certified and CAP-accredited lab, and a menu of single-gene tests for various actionable biomarkers, including two emerging therapeutic targets, RET and NTRK.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.